FDA Approves New Option in Obesity
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
The Allurion Gastric Balloon System, recently approved by the FDA, is a swallowable device aimed at assisting weight loss in adults aged 22 to 65 years with obesity, specifically for those who have struggled with traditional weight loss methods. It requires no surgery or anesthesia, as the Smart Capsule can be administered during a brief office visit. Once ingested, it inflates in the stomach to create a feeling of fullness for about four months, promoting weight management and metabolic health. The balloon can be replaced after two months, allowing for multiple treatment cycles to enhance weight loss outcomes.
1. FDA approved the Allurion Gastric Balloon System. 2. Designed for adults 22-65 with obesity. 3. Administered in a 15-minute office visit. 4. Remains in stomach for about 4 months. 5. Can have up to 2 balloons in a 10-month period. 6. Alternative to surgery and glucagon-like peptide-1s. 7. Demonstrated safety and efficacy in real-world conditions.
